About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Gonorrhoea Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Shareholder Information Analyst Coverage Corporate Governance AIM Rule 26 Advisers Annual General Meeting Careers
Press Releases Our latest press releases are available to read in this section Press Releases Date Range Explore Search Press Releases / 18 Jun 2019 Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option Press Releases / 12 Jun 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Press Releases / 14 Apr 2019 Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 Press Releases / 03 Apr 2019 Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae Press Releases / 02 Apr 2019 Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference Press Releases / 27 Mar 2019 Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 and Operational Progress Press Releases / 25 Mar 2019 Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 Press Releases / 18 Mar 2019 Summit to Present at Upcoming Conferences Press Releases / 14 Mar 2019 Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference Press Releases / 25 Feb 2019 Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data Press Releases / 13 Feb 2019 Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Press Releases / 08 Feb 2019 Summit Therapeutics to Present at the BIO CEO & Investor Conference << 1 2 3 … 25 26 >>
Press Releases / 18 Jun 2019 Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option Press Releases / 12 Jun 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Press Releases / 14 Apr 2019 Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 Press Releases / 03 Apr 2019 Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae Press Releases / 02 Apr 2019 Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference Press Releases / 27 Mar 2019 Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 and Operational Progress Press Releases / 25 Mar 2019 Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 Press Releases / 18 Mar 2019 Summit to Present at Upcoming Conferences Press Releases / 14 Mar 2019 Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference Press Releases / 25 Feb 2019 Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data Press Releases / 13 Feb 2019 Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Press Releases / 08 Feb 2019 Summit Therapeutics to Present at the BIO CEO & Investor Conference
Press Releases / 18 Jun 2019 Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option
Press Releases / 12 Jun 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
Press Releases / 14 Apr 2019 Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
Press Releases / 03 Apr 2019 Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
Press Releases / 02 Apr 2019 Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
Press Releases / 27 Mar 2019 Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 and Operational Progress
Press Releases / 25 Mar 2019 Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019
Press Releases / 14 Mar 2019 Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
Press Releases / 25 Feb 2019 Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
Press Releases / 13 Feb 2019 Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
